AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes the cost of certain medicines through price negotiations with ...

AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare ...

Dr. Kristy Hamilton, MD, FACS, a plastic and reconstructive surgeon and chair of the American Society of Plastic Surgeons Social Media Subcommittee, says doctors have been using Botox for years now to ...

AbbVie (NYSE:ABBV) has filed a lawsuit against the U.S. Department of Health and Human Services over the inclusion of Botox in Medicare price negotiations. The company argues that Botox should be ...

AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its blockbuster anti-wrinkle therapy Botox for the next round of Medicare price ...

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

Botulinum toxin — often referred to as the brand name Botox — wasn't always the Magic Eraser for fine lines and wrinkles like you might know it as today. In fact, ophthalmologist Jean Carruthers, MD, ...